Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
Open Access
- 9 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (5), 618-627
- https://doi.org/10.1038/bjc.2011.237
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 49 references indexed in Scilit:
- Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to PatientClinical Cancer Research, 2008
- Biomarkers In Early Clinical Trials: the Committed and the SkepticsClinical Cancer Research, 2008
- Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cellsBritish Journal of Cancer, 2008
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 2008
- Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2007
- Trends in the Use and Role of Biomarkers in Phase I Oncology TrialsClinical Cancer Research, 2007
- Biology of Interactions: Antiepidermal Growth Factor Receptor AgentsJournal of Clinical Oncology, 2007
- Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation ofERBB2rather thanEGFRClinical Cancer Research, 2005
- Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapyEuropean Journal of Cancer, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000